Pancreatic Cancer Clinical Trials in Detroit

Showing 61-78 of 78 trials

Identification of Biomarkers for Early Detection of Pancreatic Cancer

NCT00897494

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.

Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute75 participantsStarted Feb 2005

Detroit, Michigan, United States

COMPLETEDPHASE2< 1 mile

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

NCT00003591

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.

Pancreatic Cancer

Radiation Therapy Oncology Group122 participantsStarted Nov 1998

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +231 more locations

Identification of Biomarkers for Early Detection of Pancreatic Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Other Conditions in Detroit